Blueprint Cash And Short Term Investments vs Other Current Liab Analysis
BPMC Stock | USD 102.81 0.42 0.41% |
Blueprint Medicines financial indicator trend analysis is way more than just evaluating Blueprint Medicines Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Blueprint Medicines Corp is a good investment. Please check the relationship between Blueprint Medicines Cash And Short Term Investments and its Other Current Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
Cash And Short Term Investments vs Other Current Liab
Cash And Short Term Investments vs Other Current Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Blueprint Medicines Corp Cash And Short Term Investments account and Other Current Liab. At this time, the significance of the direction appears to have no relationship.
The correlation between Blueprint Medicines' Cash And Short Term Investments and Other Current Liab is 0.07. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Blueprint Medicines Corp, assuming nothing else is changed. The correlation between historical values of Blueprint Medicines' Cash And Short Term Investments and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Blueprint Medicines Corp are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Cash And Short Term Investments i.e., Blueprint Medicines' Cash And Short Term Investments and Other Current Liab go up and down completely randomly.
Correlation Coefficient | 0.07 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Blueprint Medicines Corp balance sheet. This account contains Blueprint Medicines investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Blueprint Medicines Corp fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Other Current Liab
Most indicators from Blueprint Medicines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Blueprint Medicines Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At present, Blueprint Medicines' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 1.12, whereas Issuance Of Capital Stock is forecasted to decline to 0.00.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 7.4M | 16.8M | 51.6M | 54.2M | Depreciation And Amortization | 6.5M | 11.7M | 11.7M | 12.2M |
Blueprint Medicines fundamental ratios Correlations
Click cells to compare fundamentals
Blueprint Medicines Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Blueprint Medicines fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 707.7M | 1.7B | 1.3B | 1.3B | 1.0B | 784.9M | |
Short Long Term Debt Total | 95.9M | 89.6M | 111.4M | 242.5M | 774.1M | 812.8M | |
Other Current Liab | 88.7M | 105.9M | 96.8M | (295.5M) | 128.0M | 134.4M | |
Total Current Liabilities | 106.5M | 130.8M | 149.8M | 183.2M | 214.9M | 225.7M | |
Total Stockholder Equity | 464.4M | 1.5B | 970.7M | 514.7M | 130.6M | 124.1M | |
Other Liab | 47.7M | 35.8M | 28.4M | 437.0M | 502.5M | 527.6M | |
Property Plant And Equipment Net | 111.1M | 101.7M | 120.9M | 115.2M | 115.7M | 63.4M | |
Current Deferred Revenue | 6.2M | 12.6M | 36.6M | 448.6M | 812K | 771.4K | |
Net Debt | (18.0M) | (595.0M) | (98.5M) | 122.7M | 702.8M | 738.0M | |
Retained Earnings | (945.2M) | (631.4M) | (1.3B) | (1.8B) | (2.3B) | (2.2B) | |
Accounts Payable | 4.8M | 4.4M | 8.3M | 2.7M | 4.7M | 3.9M | |
Cash | 113.9M | 684.6M | 209.9M | 119.7M | 71.3M | 67.7M | |
Non Current Assets Total | 190.9M | 790.6M | 698.2M | 303.3M | 240.9M | 236.9M | |
Non Currrent Assets Other | 15.4M | 11.1M | 19.8M | 26.8M | 30.6M | 32.2M | |
Other Assets | 15.4M | 569.3M | 19.8M | 26.8M | 1.0 | 0.95 | |
Cash And Short Term Investments | 548.0M | 1.5B | 1.0B | 1.1B | 710.6M | 656.9M | |
Common Stock Total Equity | 49K | 58K | 59K | 60K | 69K | 41.4K | |
Common Stock Shares Outstanding | 47.8M | 56.2M | 58.5M | 59.6M | 60.6M | 43.6M | |
Liabilities And Stockholders Equity | 707.7M | 1.7B | 1.3B | 1.3B | 1.0B | 784.9M | |
Non Current Liabilities Total | 136.9M | 117.5M | 131.7M | 652.0M | 703.7M | 738.9M | |
Other Current Assets | 379.4M | (655.9M) | (539.5M) | 35.0M | 33.4M | 35.0M | |
Other Stockholder Equity | 1.4B | 2.1B | 2.3B | 2.4B | 2.5B | 1.3B | |
Total Liab | 243.3M | 248.3M | 281.5M | 835.2M | 918.6M | 964.6M | |
Property Plant And Equipment Gross | 111.1M | 101.7M | 146.3M | 146.5M | 154.1M | 161.9M | |
Total Current Assets | 516.8M | 927.8M | 554.0M | 1.0B | 808.4M | 548.0M | |
Accumulated Other Comprehensive Income | (2.5M) | (5.2M) | (4.1M) | (10.4M) | (3.5M) | (3.7M) | |
Short Term Debt | 6.8M | 7.9M | 8.1M | 27.4M | 81.4M | 85.5M | |
Common Stock | 49K | 58K | 59K | 60K | 61K | 43.7K | |
Property Plant Equipment | 38.4M | 34.1M | 30.7M | 33.3M | 38.3M | 22.7M | |
Net Tangible Assets | 464.4M | 1.5B | 1.2B | 514.7M | 591.9M | 613.2M | |
Net Receivables | 23.4M | 25.3M | 37.0M | 36.9M | 43.2M | 45.3M | |
Short Term Investments | 369.6M | 187.2M | 267.2M | 825.3M | 639.4M | 346.5M | |
Retained Earnings Total Equity | (945.2M) | (631.4M) | (1.3B) | (1.8B) | (1.6B) | (1.6B) | |
Capital Surpluse | 1.4B | 2.1B | 2.3B | 2.4B | 2.7B | 1.5B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.82) | Revenue Per Share 4.632 | Quarterly Revenue Growth 0.519 | Return On Assets (0.24) | Return On Equity (0.80) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.